EMA Authorised: Binocrit (epoetin alfa) — Sandoz GmbH

View source ↗

Summary

EMA authorised Binocrit (epoetin alfa) by Sandoz GmbH for the treatment of anemia associated with chronic kidney disease, myelodysplastic syndromes, and in cont…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease
• Myelodysplastic Syndromes

Drugs mentioned

• Binocrit (epoetin alfa)

Snippet

Status: Authorised. Therapeutic area: Anemia;Kidney Failure, Chronic;Blood Transfusion, Autologous;Myelodysplastic Syndromes. MAH: Sandoz GmbH. Decision date: 11/07/2025